Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two cases

Frontiers in Immunology

Immunology

Guanmo Liu¹  Yiyao Xu²  Junwei Zhang²  Haitao Zhao²  Cong Ning²  Xiaobo Yang² 

[1] Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC), Beijing, China;Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC), Beijing, China;

关键词: unresectable hepatocellular carcinoma;    immunotherapy;    associating liver partition and portal vein ligation for staged hepatectomy;    future liver remnant;    immune checkpoint inhibitors;   

DOI  :  10.3389/fimmu.2023.1159885

 received in 2023-02-06, accepted in 2023-04-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can undergo radical resection. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can ultimately achieve short-term hypertrophy of the FLR in patients with viral hepatitis-related fibrosis/cirrhosis and R0 resection. However, the influence of immune checkpoint inhibitors (ICIs) on liver regeneration remains unknown. We report two patients diagnosed with Barcelona Clinic Liver Cancer (BCLC)-B stage hepatitis B virus (HBV)-related HCC who underwent pioneering ALPPS after immunotherapy without posthepatectomy liver failure (PHLF). ALPPS has been shown to be safe and feasible in patients with HCC who underwent immunotherapy previously for the first time and might provide an alternative salvage option for future conversion therapy of HCC.

【 授权许可】

Unknown   
Copyright © 2023 Ning, Liu, Zhang, Yang, Xu and Zhao